Cyclerion Therapeutics Inc (CYCN) Stock Analysis

Cyclerion Therapeutics Inc (CYCN) is a publicly traded company in the HEALTHCARE sector. It trades at $3.02, carries a market capitalization of $13.34M. This page summarizes the public market data, fundamentals, and frequently asked questions for CYCN, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

Market Sentiment

Cyclerion Therapeutics Inc currently has a Bearish sentiment score of -0.19.

About Cyclerion Therapeutics Inc

Cyclerion Therapeutics Inc. is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of innovative therapeutics for serious central nervous system (CNS) disorders. The company leverages its proprietary technology platform to develop a promising pipeline aimed at addressing significant unmet medical needs, particularly in cognitive impairment and related CNS diseases. Cyclerion's focus on advancing treatment options ...

GNG Research Analysis

GNG Research scores Cyclerion Therapeutics Inc (CYCN) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for CYCN.

Frequently Asked Questions

Does CYCN pay dividends?

Cyclerion Therapeutics Inc (CYCN) does not currently pay a regular dividend.

What is CYCN's market cap?

Cyclerion Therapeutics Inc (CYCN) has a market capitalization of $13.34M with a current stock price of $3.02.